ClinicalTrials.gg
Status unknownNCT01666964Updated Aug 16, 2012

Hormone Deficiency After Brain Injury During Combat

An observational study in Traumatic Brain Injury and Hypopituitarism, sponsored by Walter Reed National Military Medical Center. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-16.

Sponsored by Walter Reed National Military Medical Center · Observational

The sponsor has not verified this record recently (last verified Aug 2012), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

We would like to ascertain the prevalence of hypopituitarism after combat-related TBI. This will lead to enhanced awareness, recognition, and treatment of hypopituitarism, which can have life-saving ramifications and enhance quality of life and rehabilitation efforts in our combat veterans.

Read the detailed description

The prevalence of hypopituitarism after combat-related traumatic brain injury (TBI) is currently unknown. Recent civilian data on TBI show the prevalence of any pituitary hormone deficiency is as high as 80% after 12 months. While the military prevalence of hypopituitarism can be extrapolated from civilian data, a major limitation is the notably different mechanism of injury (i.e., blast) for military personnel compared to civilians (i.e., assaults, traffic accidents and falls). Little is known about the effect of shockwaves from a blast injury on central nervous system tissue, and due to the unique nature of blast-related TBI, the prevalence of pituitary dysfunction in affected service members may significantly differ from nonmilitary subjects in prior studies.

02

Conditions studied

  • Traumatic Brain Injury
  • Hypopituitarism

Keywords

  • Traumatic brain injury
  • hypopituitarism
03

In context

Brain Injuries, Traumatic

1,721 studies on the registry are indexed under Brain Injuries, Traumatic; 447 are open to participants now.

This study's planned enrollment of 200 is above the median of 117 across 557 observational studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Walter Reed National Military Medical Center is the lead sponsor of 78 studies on the registry; 20 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury that occurred 3 and 6 months prior to enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Combat veterans who are 3 or 6 months post combat-related TBI and age 18yrs or older
  • Must demonstrate capacity for
  • Must be DEERS eligible (Military healthcare beneficiary)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy (to be assessed by urine HCG)
  • Use of hormonal
  • Chronic oral or intravenous
  • Use of hormonal therapy to include estrogen and testosterone
  • Prior diagnosis of hypopituitarism prior to combat related TBI
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • 3 months post-injury

    Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe

    Other: Blast Traumatic Brain Injury

  • 6 months post-injury

    Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe

    Other: Blast Traumatic Brain Injury

Interventions

  • OtherBlast Traumatic Brain Injury

    Exposure during combat to blast-wave mediated Traumatic Brain Injury

    Also known as: bTBI

06

What researchers measure

Primary outcomes

  1. Prevalence of anterior pituitary dysfunction

    Pituitary screening blood tests: cortisol, follicle stimulating hormone, luteinizing hormone, total testosterone (males) or estradiol (females), thyrotropin, free thyroxine, prolactin, insulin-like growth factor-1. Growth-hormone deficiency will be confirmed with a glucagon stimulation test. Adrenal Insufficiency will be confirmed with an Cosyntropin stimulation test.

    Time frame: at 3 (+/- 15 days) and 6 months (+/- 15 days)

Secondary outcomes

  1. Prevalence of posterior pituitary dysfunction

    Pituitary Dysfunction: Screening Sodium. Diabetes Insipidus will be confirmed with a water deprivation test.

    Time frame: at 3 and 6 months

Other outcomes

  1. Background prevalence of hypopituitarism in a military population using the Department of Defense serum repository

    Screening labs for pituitary dysfunction repeated on frozen serum obtained prior to injury.

    Time frame: At completion of Enrollment

  2. Relationship between hypopituitarism secondary to combat-related TBI and symptom scores using the Neurobehavioral Symptom Index.

    The Neurobehavioral Symptom Index is a validated measure of cognitive and somatic symptoms after Traumatic Brain Injury.

    Time frame: 3 and 6 months post-injury

07

Study locations

1 site
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
    • Andrew J Brackbill, M.D. · Principal investigator
    • Kate H Kinnaird, M.D. · Sub investigator
    • Louis French, PhD · Sub investigator
    • Patrick W. Clyde, M.D. · Sub investigator
    • Peter McIntyre, M.D. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Dec 2014 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2012
First posted
Aug 16, 2012
Start
Oct 2012
Primary completionEst.
Dec 2014
CompletionEst.
May 2015
Last update
Aug 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01666964
Lead sponsor
Walter Reed National Military Medical Center
Collaborators
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 16, 2012
Start date
Oct 2012
Primary completion
Dec 2014 (estimated)
Completion
May 2015 (estimated)
Last update
Aug 16, 2012

Study contacts

Andrew J Brackbill, M.D.
Contact
tbiendocrine@gmail.com
301-295-5183
Andrew J. Brackbill, M.D.
principal investigator · WalterReed National Military Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion